Infliximab is a chimeric immunoglobulin (IgG1 kappa) targeting tumor necrosis factor-alpha (TNF-a), and is currently used
for the treatment of multiple inflammatory conditions. Evaluation of infliximab concentrations may be of value for all inflammatory diseases for which it
is prescribed. Primary indications for testing of infliximab include loss of response, partial response on initiation of therapy, autoimmune or hypersensitivity reactions, primary nonresponse, reintroduction after drug holiday, endoscopic/computed tomography enterography recurrence (in inflammatory bowel disease), and acute infusion reactions. Low trough concentrations may be correlated with loss of response to infliximab. Antibodies to Infliximab is also recommended if there is loss of response to the drug.
25 Jul